Tags

Type your tag names separated by a space and hit enter

A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study.
Bone Marrow Transplant 2005; 36(7):611-6BM

Abstract

Severe mucositis is a common cause of morbidity in hematopoietic stem cell transplant (HSCT) recipients. Glutamine has been shown to reduce mucositis in children receiving chemotherapy. Patients were randomized in a double-blind manner to receive glutamine or glycine at a dose of 2 g/m(2)/dose (maximum dose 4 g) twice daily until 28 days post transplant or discharge if sooner. Mucositis was graded by use of a modified Walsh scale. A total of 120 children were evaluable: 57 children received glutamine and 63 received glycine. The mean mucositis score was 3.0+/-0.3 vs 3.9+/-0.4 (P=0.07) in the glutamine and glycine groups, respectively. The glutamine group demonstrated a reduction in mean number of days of intravenous narcotics use (12.1+/-1.5 vs 19.3+/-2.8 in the glycine group, P=0.03) and total parenteral nutrition (17.3+/-1.7 vs 27.3+/-3.6 in glycine group, P=0.01). There was no statistically significant difference in toxicity between the two groups. Glutamine appears to be safe and beneficial in reducing the severity of mucositis. Strong consideration should be given to include oral glutamine supplementation as a routine part of supportive care of SCT patients.

Authors+Show Affiliations

Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA. victor.aquino@utsouthwestern.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16086046

Citation

Aquino, V M., et al. "A Double-blind Randomized Placebo-controlled Study of Oral Glutamine in the Prevention of Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation: a Pediatric Blood and Marrow Transplant Consortium Study." Bone Marrow Transplantation, vol. 36, no. 7, 2005, pp. 611-6.
Aquino VM, Harvey AR, Garvin JH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2005;36(7):611-6.
Aquino, V. M., Harvey, A. R., Garvin, J. H., Godder, K. T., Nieder, M. L., Adams, R. H., ... Sandler, E. S. (2005). A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation, 36(7), pp. 611-6.
Aquino VM, et al. A Double-blind Randomized Placebo-controlled Study of Oral Glutamine in the Prevention of Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation: a Pediatric Blood and Marrow Transplant Consortium Study. Bone Marrow Transplant. 2005;36(7):611-6. PubMed PMID: 16086046.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. AU - Aquino,V M, AU - Harvey,A R, AU - Garvin,J H, AU - Godder,K T, AU - Nieder,M L, AU - Adams,R H, AU - Jackson,G B, AU - Sandler,E S, PY - 2005/8/9/pubmed PY - 2005/12/13/medline PY - 2005/8/9/entrez SP - 611 EP - 6 JF - Bone marrow transplantation JO - Bone Marrow Transplant. VL - 36 IS - 7 N2 - Severe mucositis is a common cause of morbidity in hematopoietic stem cell transplant (HSCT) recipients. Glutamine has been shown to reduce mucositis in children receiving chemotherapy. Patients were randomized in a double-blind manner to receive glutamine or glycine at a dose of 2 g/m(2)/dose (maximum dose 4 g) twice daily until 28 days post transplant or discharge if sooner. Mucositis was graded by use of a modified Walsh scale. A total of 120 children were evaluable: 57 children received glutamine and 63 received glycine. The mean mucositis score was 3.0+/-0.3 vs 3.9+/-0.4 (P=0.07) in the glutamine and glycine groups, respectively. The glutamine group demonstrated a reduction in mean number of days of intravenous narcotics use (12.1+/-1.5 vs 19.3+/-2.8 in the glycine group, P=0.03) and total parenteral nutrition (17.3+/-1.7 vs 27.3+/-3.6 in glycine group, P=0.01). There was no statistically significant difference in toxicity between the two groups. Glutamine appears to be safe and beneficial in reducing the severity of mucositis. Strong consideration should be given to include oral glutamine supplementation as a routine part of supportive care of SCT patients. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/16086046/full_citation L2 - http://dx.doi.org/10.1038/sj.bmt.1705084 DB - PRIME DP - Unbound Medicine ER -